BJAB Cells

Unit

5 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Burkitt Lymphoma cell lines

Organism

Human

Donor History

Burkitt lymphoma

Growth Properties

Suspension

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 20% FBS

,

10 mM HEPES. Seeding density: 3 x 10⁵ cells/ml. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/BJAB-Cells/302006

SKU: 302006 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The BJAB cell line was established in 1973 from a 5-year-old African girl diagnosed with Epstein-Barr virus (EBV)-negative Burkitt’s lymphoma. This specific origin is crucial for research as it provides a distinct model for studying Burkitt’s lymphoma in the absence of EBV influence, which is common in many other lymphoma cell lines. The EBV-negative status of BJAB cells allows researchers to investigate the genetic and environmental factors contributing to lymphomagenesis without the confounding effects of the virus.

BJAB cells are often used in oncological research, especially for exploring the pathophysiology of Burkitt’s lymphoma, and for testing therapeutic strategies against it. The cell line displays many of the hallmark features of Burkitt’s lymphoma, including high proliferation rates and a characteristic immunophenotype. Its genetic stability and the robustness with which it can be cultured make it a valuable tool for in vitro experiments aimed at understanding lymphoma biology and assessing the efficacy of anti-cancer drugs.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.